Topical Resiquimod 0.01% Gel Decreases Herpes Simplex Virus Type 2 Genital Shedding: A Randomized, Controlled Trial

2007110 citationsJournal Articlebronze Open Access

Authors

Karen E. Mark · University of Washington

Lawrence Corey · University of Washington

Tze‐Chiang Meng

Amalia Magaret · Fred Hutch Cancer Center

Meei‐Li Huang · University of Washington

Stacy Selke · University of Washington

Herbert B. Slade

Stephen K. Tyring

Abstract

These findings suggest that the immunological control of HSV-2 reactivation and lesion clearance may differ and that TLR7 and TLR8 agonists can reduce the frequency of mucosal HSV-2 reactivation.

Topics & Keywords

Herpesvirus Infections and Treatments Immune Response and Inflammation Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Infectious Diseases

Volume 195, Issue 9, pp. 1324-1331

DOI: 10.1086/513276

Field-Weighted Citation Impact: 7.46